500 filings
Page 15 of 25
6-K
701jak dpuyw
22 Sep 22
Current report (foreign)
10:52am
6-K
z3wctj
19 Sep 22
Current report (foreign)
10:51am
6-K
3v9ia
31 Aug 22
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
4:08pm
6-K
djm eproll1cm
4 Aug 22
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
9:06am
6-K
t0nhdvge 2jk
3 Aug 22
Half-Year Report JANUARY – JUNE 2022
4:36pm
6-K
xl8cx
29 Jul 22
Conference Call Alert
6:13am
6-K
puvzbrqni
26 Jul 22
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
9:17am
6-K
z7h6m9duznqvxpdq
23 Jun 22
First Quarter Interim Statement JANUARY – MARCH
6:30am
6-K
r0jnpx
14 Jun 22
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
4:08pm
6-K
tkixew5j8f2ojmy
13 Jun 22
Current report (foreign)
4:07pm
6-K
1norj
10 Jun 22
Current report (foreign)
7:16am
6-K
l4ejnrjvvk4s51z oy9z
19 May 22
MorphoSys AG Reports Outcome of Annual General Meeting 2022
6:24am
6-K
g46389mx
12 May 22
Current report (foreign)
10:53am
6-K
qrz0det1 28g21
5 May 22
MorphoSys AG Reports First Quarter 2022 Financial Results
9:17am
6-K
r9xw 3vzi38ahss1c
29 Apr 22
Conference Call Alert
6:21am
6-K
c6qbqr
20 Apr 22
Current report (foreign)
9:17am
6-K
lrboat
23 Mar 22
Current report (foreign)
4:15pm
6-K
ts4xy7 298728
22 Mar 22
Current report (foreign)
4:10pm
6-K
g4c6u2o
17 Mar 22
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
9:48am
6-K
6l6el10qrc5bpg6
16 Mar 22
Current report (foreign)
5:13pm